Peter Thiel-backed Lindus Health has raised $55 million as it sets about "fixing the broken clinical trial industry." ...
Self-described as an anti-clinical research organisation, Lindus was founded in direct response to the failure of other ...
Following last year’s launches of several all-in-one CRO offerings, Lindus Health is starting 2025 strong by closing a $55 ...
CRO" running radically faster, more reliable clinical trials, announced today it has raised $55M in Series B funding. The ...
We ran a Q&A With Michael Young, co-founder of Lindus Health on the challenges of 2024 and the company’s goals for 2025.
Yet clinical trials continue to stall due to bottlenecks within Contract Research Organisations (CROs). Lindus Health describes itself as the ‘anti-CRO’ stepping in to fix a broken system and ensure a ...
The GLP-1 [glucagon-like peptide 1] agents are poised to become viable options for treating indications beyond type 2 ...